AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-32 (Canceled).

33 (New). A pharmaceutical composition comprising

at least one immunogenic peptide consisting of nine amino acids, wherein the peptide has the formula:

X_1- X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9 [SEQ ID NO:1]

wherein:

X_1, X_6, and X_9 are independently selected from tryptophan (W), phenylalanine (F), and tyrosine (Y);

X_2 is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);

X_3 is asparagine (N);

X_4 is methionine (M) or leucine (L);

X_5 is threonine (T);

X_7 is methionine (M), isoleucine (I), glutamine (Q), or leucine (L); and

X_8 is glutamine (Q or glutamate (E); or

a pharmaceutically acceptable salt of the immunogenic peptide;

wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence LEQIWNNMTWMQWDK [SEQ ID NO: 1]; and

a pharmaceutically acceptable vehicle.

34 (New). A pharmaceutical composition comprising

at least one immunogenic peptide consisting of 15 amino acids, wherein the peptide has the formula:

R_1-R_2-R-$_3$-R_4-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-R5.R_6 [SEQ ID NO:1]

wherein:

R_1 is leucine (L); glutamine (Q), tyrosine (Y) or aspartate (D);

R_2 is glutamate (E);aspartate (D) or asparagine (N);

R_3 is glutamine (Q) aspartate (D) or serine (S);

R_4 is isoleucine (I);

X_1, X_6, and X_9 are independently selected from tryptophan (W), phenylalanine (F), and tyrosine (Y);

X_2 is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);

X_3 is asparagine (N);

X_4 is methionine (M) or leucine (L);

X_5 is threonine (T);

X_7 is methionine (M), isoleucine (I), glutamine (Q), or leucine (L); and

X_8 is glutamine (Q) or glutamate (E); and

R5 is glutamate (E) or aspartate (D);

R_6 is lysine (K), glutamine (Q) or arginine (R); or

a pharmaceutically acceptable salt of the immunogenic peptide;

wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence LEQIWNNMTWMQWDK [SEQ ID NO: 1]; and

a pharmaceutically acceptable vehicle.

35 (New). A pharmaceutical composition comprising

at least one immunogenic peptide consisting of up to 31 amino acids, wherein the peptide has the formula:

R_7-X_1- X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11} [SEQ ID NO:1]

wherein:

R_7 is an amino acid chain of up to 20 amino acids other than aromatic amino acids;

X_1, X_6, and X_9 are independently selected from tryptophan (W), phenylalanine (F), and tyrosine (Y);

X_2 is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);

X_3 is asparagine (N);

X_4 is methionine (M) or leucine (L);

X_5 is threonine (T);

X_7 is methionine (M), isoleucine (I), glutamine (Q), or leucine (L);

X_8 is glutamine (Q) or glutamate (E);

X_{10} is aspartate (D) or glutamate (E)

X_{11} is lysine (K) glutamine (Q) or arginine (R); or

a pharmaceutically acceptable salt of the immunogenic peptide;

wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence LEQIWNNMTWMQWDK (CBD1) [SEQ ID NO: 1]; and

a pharmaceutically acceptable vehicle.

36 (New). The pharmaceutical composition as claimed in claim 34, wherein the immunogenic peptide has the formula:

L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID No. 2).

37 (New). The pharmaceutical composition of claim 35, wherein the immunogenic peptide has the formula:

C-T-T-A-V-P-W-N-A-S-W-S-N-K-S-L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID No. 4), or

C-H-T-T-V-P-W-P-N-D-S-L-T-P-D-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID No. 5).

38 (New). The pharmaceutical composition as claimed in claim 36, wherein the peptide is glycosylated or phosphorylated.

39 (New). The pharmaceutical composition as claimed in claim 36, wherein the peptide contains two cysteine residues that form a disulfide bridge.

40 (New). The pharmaceutical composition as claimed in claim 36, wherein the pharmaceutically acceptable salt is an organic or inorganic acid salt formed with free amino groups of the peptide.

41 (New). The pharmaceutical composition as claimed in claim 39, wherein acid salt is a salt of phosphoric acid, hydrochloric acid, acetic acid, or oxalic acid.

42 (New). The pharmaceutical composition as claimed in claim 40, wherein the pharmaceutically acceptable vehicle comprises saline, dextrose, glycerol, water, ethanol, or combinations thereof.

43 (New). The pharmaceutical composition as claimed in claim 41, which comprises an adjuvant.

44 (New). The pharmaceutical composition as claimed in claim 40, wherein the composition is encapsulated in a polymer, liposome, or micelle.

45 (New). A method of monitoring SIV infection in a monkey, wherein the method comprises:

intramuscularly, subcutaneously, or intravenously administering to a SIV-infected monkey a pharmaceutical composition as claimed in any one of claims 35 and 37 in an amount sufficient to elicit a neutralizing antibody response to SIV; and

detecting neutralizing antibody titer in the monkey.

46 (New). A pharmaceutical composition comprising

at least one unglycosylated immunogenic peptide consisting of nine amino acids, wherein the peptide has the formula:

X_1- X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9 [SEQ ID NO:1]

wherein:

X_1, X_6, and X_9 are independently selected from tryptophan (W), phenylalanine (F), and tyrosine (Y);

X_2 is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);

X_3 is asparagine (N);

X_4 is methionine (M) or leucine (L);

X_5 is threonine (T);

X_7 is methionine (M), isoleucine (I), glutamine (Q), or leucine (L); and

X_8 is glutamine (Q); or

a pharmaceutically acceptable salt of the immunogenic peptide;

wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence LEQIWNNMTWMQWDK [SEQ ID NO: 1]; and

a pharmaceutically acceptable vehicle.

47 (New). A pharmaceutical composition comprising

at least one unglycosylated immunogenic peptide consisting of 13 amino acids, wherein the peptide has the formula:

R_1-R_2-R-$_3$-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-R_4 [SEQ ID NO:1]

wherein:

R_1 is leucine (L);

R_2 is glutamine (E);

R_3 is glutamate (Q)

X_1, X_6, and X_9 are independently selected from tryptophan (W), phenylalanine (F), and tyrosine (Y);

X_2 is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);

X_3 is asparagine (N);

X_4 is methionine (M) or leucine (L);

X_5 is threonine (T);

X_7 is methionine (M), isoleucine (I), glutamine (Q), or leucine (L);

X_8 is glutamine (Q) or glutamate (E); and

R_4 is lycine (K); or

a pharmaceutically acceptable salt of the immunogenic peptide;

wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence LEQIWNNMTWMQWDK [SEQ ID NO: 1]; and

a pharmaceutically acceptable vehicle.

48 (New). A pharmaceutical composition comprising

at least one unglycosylated immunogenic peptide consisting of up to 31 amino acids, wherein the peptide has the formula:

R_5-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11} [SEQ ID NO:1]

wherein:

R_5 is an amino acid chain of up to 20 amino acids other than aromatic amino acids;

X_1, X_6, and X_9 are independently selected from tryptophan (W), phenylalanine (F), and tyrosine (Y);

X_2 is asparagine (N), aspartate (D), glutamate (E), or glutamine (Q);

X_3 is asparagine (N);

X_4 is methionine (M) or leucine (L);

X_5 is threonine (T);

X_7 is methionine (M), isoleucine (I), glutamine (Q), or leucine (L);

X_8 is glutamine (Q);

X_{10} is aspartate (D); and

X_{11} is lysine (K); or

a pharmaceutically acceptable salt of the immunogenic peptide;

wherein the immunogenic peptide or pharmaceutically acceptable salt of the immunogenic peptide immunologically reacts with antibodies raised against the CBD-1 peptide of sequence LEQIWNNMTWMQWDK [SEQ ID NO: 1]; and

a pharmaceutically acceptable vehicle.

49 (New). The pharmaceutical composition as claimed in claim 48, wherein the immunogenic peptide has the formula:

L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID No. 2),

C-T-T-A-V-P-W-N-A-S-W-S-N-K-S-L-E-Q-I-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID No. 4), or

C-H-T-T-V-P-W-P-N-D-S-L-T-P-D-W-N-N-M-T-W-M-Q-W-D-K (SEQ ID No. 5).

50 (New). The pharmaceutical composition as claimed in claim 49, wherein the peptide is glycosylated or phosphorylated.

51 (New). The pharmaceutical composition as claimed in claim 49, wherein the peptide contains two cysteine residues that form a disulfide bridge.

52 (New). The pharmaceutical composition as claimed in claim 49, wherein the pharmaceutically acceptable salt is an organic or inorganic acid salt formed with free amino groups of the peptide.

53 (New). The pharmaceutical composition as claimed in claim 49, wherein acid salt is a salt of phosphoric acid, hydrochloric acid, acetic acid, or oxalic acid.

54 (New). The pharmaceutical composition as claimed in claim 53, wherein the pharmaceutically acceptable vehicle comprises saline, dextrose, glycerol, water, ethanol, or combinations thereof.

55 (New). The pharmaceutical composition as claimed in claim 54, which comprises an adjuvant.

56 (New). The pharmaceutical composition as claimed in claim 53, wherein the composition is encapsulated in a polymer, liposome, or micelle.

57 (New). A method of monitoring SIV infection in a monkey, wherein the method comprises:

intramuscularly, subcutaneously, or intravenously administering to a SIV-infected monkey a pharmaceutical composition as claimed in claim 49 in an amount sufficient to elicit a neutralizing antibody response to SIV; and

detecting neutralizing antibody titer in the monkey.